Table 1.

Baseline patient characteristics

	Placebo N = 93	Etoricoxib 90 mg N = 103	Etoricoxib 120 mg N = 92	Naproxen 1000 mg N = 99
Age (years), mean (SD)	43.7 (12.1)	43.1 (12.1)	42.5 (12.0)	45.0 (11.4)
Female (%)	20.4	26.2	21.7	20.2
History of iritis (%)	33.3	37.9	31.5	31.3
History of chronic peripheral arthritis (%)	39.8	39.8	39.1	41.4
History of corticosteroid use (%)	32.3	23.3	23.9	22.2
Concomitant DMARD use (%)*	19.4	26.2	19.6	23.2
Baseline BASDAI (100-mm VAS), mean (SD)	54.1 (27.0)	56.9 (22.5)	55.2 (25.1)	54.1 (23.2)
Baseline spine pain (100-mm VAS), mean (SD)	77.2 (15.2)	78.0 (13.9)	78.0 (14.2)	77.2 (16.5)

*Auranofin, azathioprine, cyclosporine, leflunomide, methotrexate, methotrexate sodium, or sulfasalazine

DMARD: disease-modifying antirheumatic drug; SD: standard deviation; VAS: visual analog scale